With FDA approval of Wegovy pill, new era of oral GLP-1 weight loss drugs begins [CNN]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNN
how patients can take medicines in a class of drugs that has revolutionized obesity treatment. The drug, which Novo Nordisk calls simply the Wegovy pill, uses the same active ingredient – semaglutide – that powers the original Wegovy, along with its sister drug for diabetes, Ozempic. Both Wegovy and Ozempic, which mimic the hormone GLP-1, are given as weekly injections, as are rival drugs from Eli Lilly, called Zepbound and Mounjaro. Altogether, about 1 in 8 US adults say they're currently taking one of the medicines, according to data from health policy research group KFF. The Wegovy pill showed roughly similar weight loss and side effects in clinical trials as the Wegovy shot, and will be available by prescription in the US in January, according to Novo Nordisk. “We believe it will expand access and options for patients,” Dr. Jason Brett, principal US medical head for Novo Nordisk, told CNN in an interview. “We know there are some patients who just won't take an injectable m
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk [MSNBC.com]MSNBC.com
- FDA approves Wegovy pill for weight loss, the first daily oral medication of its kind [CBS News]CBS News
- FDA approves Wegovy weight loss pill from Novo Nordisk [MSNBC.com]MSNBC.com
- FDA approves Wegovy weight-loss pill from Novo Nordisk [USA TODAY]USA TODAY
- US regulators approve Wegovy pill for weight loss [Yahoo! Finance Canada]Yahoo! Finance Canada
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website